← Back to headlines
Gilead Acquires Full Control of Multiple Myeloma Therapy for $7.8 Billion
Gilead Sciences has announced a $7.8 billion payment to take full control of a promising multiple myeloma therapy, expanding its oncology portfolio.
23 Feb, 13:16 — 23 Feb, 13:16
ℹOnly 1 source covers this story
